Oncogenic CTNNB1 and TP53 mutations resulting in function loss are known to be inducing glycolysis pathways in cancer, which contribute to the progression of tumors and developing resistance to chemotherapy in tumors [14, 15]. Here, TP53 is linked to cancer.